Company Analysis Alnylam Pharmaceuticals, Inc.
1. Summary
Advantages
- The stock's return over the last year (70.2%) is higher than the sector average (-29.77%).
- The company's current efficiency (ROE=199.53%) is higher than the sector average (ROE=9.61%)
Disadvantages
- Price (286.1 $) is higher than fair price (237.35 $)
- Dividends (0%) are below the sector average (0.5491%).
- Current debt level 29.17% has increased over 5 years from 1.91%.
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Alnylam Pharmaceuticals, Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | 7.2% | -16.4% | 1.7% |
| 90 days | 14.5% | -46.1% | 6.1% |
| 1 year | 70.2% | -29.8% | 33.5% |
ALNY vs Sector: Alnylam Pharmaceuticals, Inc. has outperformed the "Healthcare" sector by 99.96% over the past year.
ALNY vs Market: Alnylam Pharmaceuticals, Inc. has outperformed the market by 36.68% over the past year.
Stable price: ALNY is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: ALNY with weekly volatility of 1.35% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (286.1 $) is higher than the fair price (237.35 $).
Price is higher than fair: The current price (286.1 $) is 17% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (0) is lower than that of the sector as a whole (48.77).
P/E vs Market: The company's P/E (0) is lower than that of the market as a whole (48.05).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (-108.14) is lower than that of the sector as a whole (4.82).
P/BV vs Market: The company's P/BV (-108.14) is lower than that of the market as a whole (3.1).
4.4. P/S
P/S vs Sector: The company's P/S indicator (13.05) is lower than that of the sector as a whole (33.76).
P/S vs Market: The company's P/S indicator (13.05) is higher than that of the market as a whole (10.14).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-112.79) is lower than that of the sector as a whole (-22.12).
EV/Ebitda vs Market: The company's EV/Ebitda (-112.79) is lower than that of the market as a whole (19.1).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -10.06% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-10.06%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-9.16%).
5.4. ROE
ROE vs Sector: The company's ROE (199.53%) is higher than that of the sector as a whole (9.61%).
ROE vs Market: The company's ROE (199.53%) is higher than that of the market as a whole (10.87%).
5.5. ROA
ROA vs Sector: The company's ROA (-11.49%) is lower than that of the sector as a whole (0.3359%).
ROA vs Market: The company's ROA (-11.49%) is lower than that of the market as a whole (6.5%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (-56.48%) is lower than that of the sector as a whole (7.63%).
ROIC vs Market: The company's ROIC (-56.48%) is lower than that of the market as a whole (10.79%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.5491%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
8. Insider trades
8.1. Insider trading
Insider Buying Exceeds insider sales by 100% over the last 3 months.
8.2. Latest transactions
| Transaction date | Insider | Type | Price | Volume | Quantity |
|---|---|---|---|---|---|
| 12.08.2024 | Fitzgerald Kevin Joseph Officer |
Purchase | 269.52 | 5 936 180 | 22 025 |
| 01.08.2024 | Greenstreet Yvonne Chief Executive Officer |
Sale | 270 | 4 089 960 | 15 148 |
| 01.08.2024 | Greenstreet Yvonne Chief Executive Officer |
Purchase | 85 | 1 287 580 | 15 148 |
| 11.07.2024 | Greenstreet Yvonne Chief Executive Officer |
Sale | 261 | 1 851 270 | 7 093 |
| 25.06.2024 | SCHULMAN AMY W Director |
Sale | 240 | 2 040 000 | 8 500 |
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
